- Home
- IMNM vs DGICA Comparison
IMNM vs DGICA Comparison
Compare IMNM & DGICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- DGICA
- Stock Information
- Founded
- IMNM 2006
- DGICA 1986
- Country
- IMNM United States
- DGICA United States
- Employees
- IMNM N/A
- DGICA N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- DGICA Property-Casualty Insurers
- Sector
- IMNM Health Care
- DGICA Finance
- Exchange
- IMNM Nasdaq
- DGICA Nasdaq
- Market Cap
- IMNM 585.5M
- DGICA 503.4M
- IPO Year
- IMNM 2020
- DGICA N/A
- Fundamental
- Price
- IMNM $11.08
- DGICA $14.73
- Analyst Decision
- IMNM Strong Buy
- DGICA
- Analyst Count
- IMNM 5
- DGICA 0
- Target Price
- IMNM $28.60
- DGICA N/A
- AVG Volume (30 Days)
- IMNM 1.0M
- DGICA 101.8K
- Earning Date
- IMNM 03-27-2025
- DGICA 02-20-2025
- Dividend Yield
- IMNM N/A
- DGICA 4.68%
- EPS Growth
- IMNM N/A
- DGICA 148.60
- EPS
- IMNM N/A
- DGICA 0.74
- Revenue
- IMNM $10,129,000.00
- DGICA $979,119,004.00
- Revenue This Year
- IMNM N/A
- DGICA N/A
- Revenue Next Year
- IMNM N/A
- DGICA $5.78
- P/E Ratio
- IMNM N/A
- DGICA $19.77
- Revenue Growth
- IMNM N/A
- DGICA 7.44
- 52 Week Low
- IMNM $8.97
- DGICA $12.26
- 52 Week High
- IMNM $30.96
- DGICA $17.00
- Technical
- Relative Strength Index (RSI)
- IMNM 54.91
- DGICA 47.93
- Support Level
- IMNM $10.29
- DGICA $14.33
- Resistance Level
- IMNM $11.43
- DGICA $14.94
- Average True Range (ATR)
- IMNM 0.77
- DGICA 0.29
- MACD
- IMNM 0.18
- DGICA 0.08
- Stochastic Oscillator
- IMNM 85.23
- DGICA 76.40
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.